At the beginning of August, 2009, Mellow Hope has finished the clinical trial of Cerebroprotein Hydrolysate for Injection (Brand name: NUTRIPROTEIN) in India. This biological product is a unique nutriment for the brain. It helps CNS in multiple ways, regulating and improving nerve cell metabolism, promoting synapse generation, inducing nerve cell differentiation, protecting nerve cells against damages by ischemia and neurotoxins etc.

This clincial trial is a multicentral one, authorized by Mellow Hope and sponsored by our partner Lupin Limited which is one of the top 3 pharmaceutical companies in India. The aim of this trial is to evaluate the efficacy and safety of this product in the management of subjects with Dementia in an open labeled, prospective, phase-III clinical trial. Through this clincal trial, this product has been approved with very good efficacy and safety.

With the completion of this clinical trial, we are expected to receive the registraion approval for NUTRIPROTEIN within three months in India. As soon as we get the approval, we will launch this product in local market. Without any competitors in India, we will win a large marketshare.